Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2008

01.10.2008 | Breast Oncology

Factors Associated with Lymph Node Assessment in Ductal Carcinoma in situ: Analysis of 1988–2002 Seer Data

verfasst von: Matthew R. Porembka, MD, Rebecca L. Abraham, BS, Julianne A. Sefko, BS, Anjali D. Deshpande, PhD, MPH, Donna B. Jeffe, PhD, Julie A. Margenthaler, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Ductal carcinoma in situ (DCIS) represents 20–30% of mammographically detected breast cancers, but the role of lymph node assessment (LNA) in women with DCIS remains unclear.

Methods

Using the 1988–2002 Surveillance, Epidemiology, and End Results (SEER) Program data, we conducted a case–control study to identify variables associated with (1) LNA in DCIS patients and (2) use of axillary lymph node dissection (ALND) compared with sentinel lymph node biopsy (SLNB). Using separate multivariable logistic regression models, we identified patient and tumor-related factors associated with LNA (1988–2002) and with the method used (recorded only in 1998–2002). We report adjusted odds ratios (aORs) and 95% confidence intervals (CIs).

Results

Of 23,502 women with DCIS, 37% underwent mastectomy and 63% underwent breast-conservation therapy (BCT); 6,650 cases (28%) underwent LNA. Women younger than 80 years (aOR 1.47; 95% CI 1.24–1.75) or who had mastectomy (aOR 11.06; 95% CI 10.30–11.90), tumor size greater than 9 mm (aORs ranged from 1.27–1.97 for 10-mm increments from 10 to 50 mm or more) or poorly differentiated grade (aOR 1.33; 95% CI 1.11–1.55) were more likely to have had a LNA. From 1998 to 2002, 10,637 women underwent resection for DCIS (21% mastectomy; 79% BCT); of these, 2,219 (21%) had LNA (73% mastectomy; 27% BCT). Mastectomy patients were 3.52 times more likely to receive ALND (95% CI 2.71–4.57) than SLNB, after controlling for other factors.

Conclusion

Optimal guidelines for use of LNA in DCIS have not been defined. However, there appeared to be a persistent and excessive utilization of ALND for LNA in women with DCIS (1998–2002).
Literatur
1.
Zurück zum Zitat Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913–8PubMedCrossRef Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913–8PubMedCrossRef
2.
Zurück zum Zitat Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI, Consensus Conference Committee. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Cancer 2000; 88:946–54 Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI, Consensus Conference Committee. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Cancer 2000; 88:946–54
3.
Zurück zum Zitat Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000; 160:953–8PubMedCrossRef Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000; 160:953–8PubMedCrossRef
4.
Zurück zum Zitat Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672–85PubMed Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672–85PubMed
5.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371–88PubMedCrossRef Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371–88PubMedCrossRef
6.
Zurück zum Zitat Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993–2000PubMedCrossRef Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993–2000PubMedCrossRef
7.
Zurück zum Zitat Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355:528–33PubMedCrossRef Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355:528–33PubMedCrossRef
8.
Zurück zum Zitat Fisher ES, Welch HG. Avoiding the unintended consequences of growth in medical care: how might more be worse? JAMA 1999; 281:446–53PubMedCrossRef Fisher ES, Welch HG. Avoiding the unintended consequences of growth in medical care: how might more be worse? JAMA 1999; 281:446–53PubMedCrossRef
9.
Zurück zum Zitat Morrow M, Venta L, Stinson T, et al. Prospective comparison of stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients. Ann Surg 2001; 233:537–41PubMedCrossRef Morrow M, Venta L, Stinson T, et al. Prospective comparison of stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients. Ann Surg 2001; 233:537–41PubMedCrossRef
10.
Zurück zum Zitat Darling ML, Smith DN, Lester SC, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol 2000; 175:1341–6PubMed Darling ML, Smith DN, Lester SC, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol 2000; 175:1341–6PubMed
11.
Zurück zum Zitat Silverstein MJ, Lagios MD, Recht A, et al. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 2005; 201:586–97PubMedCrossRef Silverstein MJ, Lagios MD, Recht A, et al. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 2005; 201:586–97PubMedCrossRef
12.
Zurück zum Zitat Hoorntje LE, Peeters PH, Mali WP, et al. Is stereotactic large-core needle biopsy beneficial prior to surgical treatment in BI-RADS 5 lesions? Breast Cancer Res Treat 2004; 86:165–70PubMedCrossRef Hoorntje LE, Peeters PH, Mali WP, et al. Is stereotactic large-core needle biopsy beneficial prior to surgical treatment in BI-RADS 5 lesions? Breast Cancer Res Treat 2004; 86:165–70PubMedCrossRef
13.
Zurück zum Zitat Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200:516–26PubMedCrossRef Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200:516–26PubMedCrossRef
14.
Zurück zum Zitat Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am 2000; 38:791–807PubMedCrossRef Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am 2000; 38:791–807PubMedCrossRef
15.
Zurück zum Zitat Liberman L, Drotman M, Morris EA, et al. Imaging-histologic discordance at percutaneous breast biopsy. Cancer 2000; 89:2538–46PubMedCrossRef Liberman L, Drotman M, Morris EA, et al. Imaging-histologic discordance at percutaneous breast biopsy. Cancer 2000; 89:2538–46PubMedCrossRef
16.
Zurück zum Zitat Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218:497–502PubMed Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218:497–502PubMed
17.
Zurück zum Zitat Jackman RJ, Nowels KW, Rodriguez-Soto J, et al. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology 1999; 210:799–805PubMed Jackman RJ, Nowels KW, Rodriguez-Soto J, et al. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology 1999; 210:799–805PubMed
18.
Zurück zum Zitat Hoorntje LE, Schipper ME, Peeters PH, et al. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003; 10:748–53PubMedCrossRef Hoorntje LE, Schipper ME, Peeters PH, et al. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003; 10:748–53PubMedCrossRef
19.
Zurück zum Zitat Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000; 7:15–20PubMedCrossRef Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000; 7:15–20PubMedCrossRef
20.
Zurück zum Zitat Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994; 73:664–7PubMedCrossRef Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994; 73:664–7PubMedCrossRef
21.
Zurück zum Zitat Veronesi P, Intra M, Vento AR, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005; 14:520–2PubMedCrossRef Veronesi P, Intra M, Vento AR, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005; 14:520–2PubMedCrossRef
22.
Zurück zum Zitat Kelly TA, Kim JA, Patrick R, et al. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 2003; 186:368–70PubMedCrossRef Kelly TA, Kim JA, Patrick R, et al. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 2003; 186:368–70PubMedCrossRef
23.
Zurück zum Zitat Pendas S, Jakub J, Giuliano R, et al. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control 2004; 11:231–5PubMed Pendas S, Jakub J, Giuliano R, et al. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control 2004; 11:231–5PubMed
24.
Zurück zum Zitat Winchester DJ, Menck HR, Winchester DP. The National Cancer Data Base report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy. Cancer 1997; 80:162–7PubMedCrossRef Winchester DJ, Menck HR, Winchester DP. The National Cancer Data Base report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy. Cancer 1997; 80:162–7PubMedCrossRef
25.
Zurück zum Zitat Winchester DJ, Menck HR, Winchester DP. National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 1997; 132:660–5PubMed Winchester DJ, Menck HR, Winchester DP. National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 1997; 132:660–5PubMed
26.
Zurück zum Zitat Winchester DP, Menck HR, Osteen RT, et al. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol 1995; 2:207–13PubMedCrossRef Winchester DP, Menck HR, Osteen RT, et al. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol 1995; 2:207–13PubMedCrossRef
27.
Zurück zum Zitat Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996; 78:1838–43PubMedCrossRef Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996; 78:1838–43PubMedCrossRef
28.
Zurück zum Zitat Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96:443–8PubMed Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96:443–8PubMed
29.
Zurück zum Zitat Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25:767–72PubMedCrossRef Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25:767–72PubMedCrossRef
30.
Zurück zum Zitat Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906–20PubMedCrossRef Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906–20PubMedCrossRef
31.
Zurück zum Zitat Parker RG, Berkbigler D, Rees K, et al. Axillary node dissection in ductal carcinoma in situ. Am J Clin Oncol 1998; 21:109–10PubMedCrossRef Parker RG, Berkbigler D, Rees K, et al. Axillary node dissection in ductal carcinoma in situ. Am J Clin Oncol 1998; 21:109–10PubMedCrossRef
32.
Zurück zum Zitat Kitchen PR, Cawson JN, Krishnan CM, et al. Axillary dissection and ductal carcinoma in situ of the breast: a change in practice. Aust N Z J Surg 2000; 70:419–22PubMedCrossRef Kitchen PR, Cawson JN, Krishnan CM, et al. Axillary dissection and ductal carcinoma in situ of the breast: a change in practice. Aust N Z J Surg 2000; 70:419–22PubMedCrossRef
33.
Zurück zum Zitat Sakorafas GH, Farley DR. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 2003; 12:221–40PubMedCrossRef Sakorafas GH, Farley DR. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 2003; 12:221–40PubMedCrossRef
34.
Zurück zum Zitat The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists. CMAJ 1998; 158(Suppl 3):S27–34 The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists. CMAJ 1998; 158(Suppl 3):S27–34
35.
Zurück zum Zitat Carlson RW, McCormick B. Update: NCCN breast cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 Suppl 1:S7–11PubMed Carlson RW, McCormick B. Update: NCCN breast cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 Suppl 1:S7–11PubMed
36.
Zurück zum Zitat Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society guidelines for the early detection of breast cancer: Update 1997. CA Cancer J Clin 1997; 47:150–3PubMedCrossRef Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society guidelines for the early detection of breast cancer: Update 1997. CA Cancer J Clin 1997; 47:150–3PubMedCrossRef
37.
Zurück zum Zitat U.S. Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med 2002; 137:344–7 U.S. Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med 2002; 137:344–7
38.
Zurück zum Zitat Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26:313–25PubMedCrossRef Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26:313–25PubMedCrossRef
39.
Zurück zum Zitat Pagan JA, Asch DA, Brown CJ, et al. Lack of community insurance and mammography screening rates among insured and uninsured women. J Clin Oncol 2008; 26:1865–70PubMedCrossRef Pagan JA, Asch DA, Brown CJ, et al. Lack of community insurance and mammography screening rates among insured and uninsured women. J Clin Oncol 2008; 26:1865–70PubMedCrossRef
40.
Zurück zum Zitat Partridge A, Adloff K, Blood E, et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008; 100:243–51PubMedCrossRef Partridge A, Adloff K, Blood E, et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008; 100:243–51PubMedCrossRef
41.
Zurück zum Zitat Cody HS. Sentinel lymph node biopsy for breast cancer: indications, contraindications, and new directions. J Surg Oncol 2007; 95:440–2PubMedCrossRef Cody HS. Sentinel lymph node biopsy for breast cancer: indications, contraindications, and new directions. J Surg Oncol 2007; 95:440–2PubMedCrossRef
42.
Zurück zum Zitat Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol 2001; 8:275–7PubMedCrossRef Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol 2001; 8:275–7PubMedCrossRef
43.
Zurück zum Zitat Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000; 7:15–20PubMedCrossRef Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000; 7:15–20PubMedCrossRef
44.
Zurück zum Zitat Leidenius M, Salmenkivi K, Von Smitten K, et al. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol 2006; 94:380–4PubMedCrossRef Leidenius M, Salmenkivi K, Von Smitten K, et al. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol 2006; 94:380–4PubMedCrossRef
45.
Zurück zum Zitat Tunon-de-Lara C, Giard S, Buttarelli M, et al. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy. Breast J 2008; 14:135–40PubMedCrossRef Tunon-de-Lara C, Giard S, Buttarelli M, et al. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy. Breast J 2008; 14:135–40PubMedCrossRef
46.
Zurück zum Zitat Dominguez FJ, Golshan M, Black DM, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008; 15:268–73PubMedCrossRef Dominguez FJ, Golshan M, Black DM, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008; 15:268–73PubMedCrossRef
Metadaten
Titel
Factors Associated with Lymph Node Assessment in Ductal Carcinoma in situ: Analysis of 1988–2002 Seer Data
verfasst von
Matthew R. Porembka, MD
Rebecca L. Abraham, BS
Julianne A. Sefko, BS
Anjali D. Deshpande, PhD, MPH
Donna B. Jeffe, PhD
Julie A. Margenthaler, MD
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9947-5

Weitere Artikel der Ausgabe 10/2008

Annals of Surgical Oncology 10/2008 Zur Ausgabe

Chirurginnen nehmen sich Zwischenfälle im OP besonders zu Herzen

05.06.2024 Allgemeine Chirurgie Nachrichten

Selbstverschuldete Fehler oder unerwartete Komplikationen machen jungen Chirurginnen und Operateuren mit Migrationshintergrund offenbar besonders zu schaffen. Benötigt werden routinemäßige Programme zum Umgang mit Zwischenfällen im OP.

Schützt auch die medikamentöse Gewichtsreduktion vor Krebs?

03.06.2024 ASCO 2024 Kongressbericht

Offenbar muss es nicht immer die bariatrische Chirurgie sein, wenn es darum geht, durch deutlichen Gewichtsverlust auch das Krebsrisiko günstig zu beeinflussen. Eine große Kohortenanalyse zur Behandlung mit GLP-1-Agonisten wurde dazu auf der ASCO-Tagung vorgestellt.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.